{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T22:09:11Z","timestamp":1770070151011,"version":"3.49.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-025-04502-6","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T10:52:28Z","timestamp":1770029548000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hepcidin concentration and effect on iron homeostasis in patients with adrenocortical carcinoma and benign adrenal lesions \u2013 a pilot study"],"prefix":"10.1007","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4068-7754","authenticated-orcid":false,"given":"Aleksandra","family":"Krygier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2205-4558","authenticated-orcid":false,"given":"Dorota","family":"Filipowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0175-6208","authenticated-orcid":false,"given":"Barbara","family":"Brominska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9085-4330","authenticated-orcid":false,"given":"Hanna","family":"Komarowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3661-3274","authenticated-orcid":false,"given":"Ewelina","family":"Szczepanek-Parulska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6296-7220","authenticated-orcid":false,"given":"Marek","family":"Ruchala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"issue":"1","key":"4502_CR1","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1093\/ejendo\/lvad066","volume":"189","author":"M Fassnacht","year":"2023","unstructured":"M. Fassnacht et al., European society of endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European network for the study of adrenal tumors. Eur. J. Endocrinol. 189(1), G1\u2013G42 (2023)","journal-title":"Eur. J. Endocrinol."},{"issue":"4","key":"4502_CR2","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-18-0608","volume":"179","author":"M Fassnacht","year":"2018","unstructured":"M. Fassnacht, O. Dekkers, T. Else, E. Baudin, European society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European network for the study of adrenal tumors. Eur. J. Endocrinol. 179(4), G1\u2013G46 (2018)","journal-title":"Eur. J. Endocrinol."},{"issue":"11","key":"4502_CR3","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","volume":"31","author":"M Fassnacht","year":"2020","unstructured":"M. Fassnacht, G. Assie, E. Baudin, Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 31(11), 1476\u20131490 (2020)","journal-title":"Ann. Oncol."},{"issue":"4","key":"4502_CR4","doi-asserted-by":"publisher","first-page":"339","DOI":"10.5603\/ep.101677","volume":"5","author":"D Hadkiewicz-Junak","year":"2024","unstructured":"D. Hadkiewicz-Junak, M. Dedecjus, U. Ambroziak, Polish diagnostic and therapeutic recommendations for adrenocortical carcinoma. Endokrynol Pol. 5(4), 339\u2013358 (2024)","journal-title":"Endokrynol Pol."},{"key":"4502_CR5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1146\/annurev-med-043021-032816","volume":"27","author":"E Nemeth","year":"2023","unstructured":"E. Nemeth, T. Ganz, Hepcidin and iron in health and disease. Annu. Rev. Med. 27, 74:261\u2013277 (2023)","journal-title":"Annu. Rev. Med."},{"key":"4502_CR6","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jtemb.2019.07.009","volume":"56","author":"B Zhu","year":"2019","unstructured":"B. Zhu, Q. Zhi, Q. Xie, Reduced expression of ferroportin1 and ceruloplasmin predicts poor prognosis in adrenocortical carcinoma. J. Trace Elem. Med. Biol. 56, 52\u201359 (2019)","journal-title":"J. Trace Elem. Med. Biol."},{"issue":"4","key":"4502_CR7","doi-asserted-by":"publisher","first-page":"e928","DOI":"10.20883\/medical.e928","volume":"92","author":"J Nowak","year":"2024","unstructured":"J. Nowak, J. Walkowiak, Study designs in medical research and their key characteristics. JMS. 92(4), e928 (2024)","journal-title":"JMS"},{"issue":"9","key":"4502_CR8","first-page":"3530","volume":"5","author":"R Szabo","year":"2021","unstructured":"R. Szabo, C. Petrisor, S. Tranca, Vitamin D and iron levels correlate weakly with Hepcidin levels in postoperative patients with digestive neoplasms undergoing open abdominal surgery. Eur. Rev. Med. Pharmacol. Sci. 5(9), 3530\u20133535 (2021)","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"4502_CR9","first-page":"165","volume":"12","author":"T Shibabaw","year":"2020","unstructured":"T. Shibabaw, B. Teferi, M.D. Molla, B. yelign, Inflammation mediated Hepcidin-Ferroportin pathway and its therapeutic window in breast cancer. Breast Cancer. 12, 165\u2013180 (2020)","journal-title":"Breast Cancer"},{"key":"4502_CR10","doi-asserted-by":"publisher","first-page":"612144","DOI":"10.3389\/fimmu.2021.612144","volume":"12","author":"Y Fan","year":"2021","unstructured":"Y. Fan, B. Liu, F. Chen, Z. Song, Hepcidin upregulation in lung cancer: A potential therapeutic target associated with immune infiltration. Ront Immunol. 12, 612144 (2021)","journal-title":"Front Immunol."},{"key":"4502_CR11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41416-022-01753-2","volume":"27","author":"JH Joachim","year":"2022","unstructured":"J.H. Joachim, K. Metha, J. Hepcidin in hepatocellular carcinoma. Br. J. Cancer. 27, 185\u2013192 (2022)","journal-title":"Br. J. Cancer"},{"issue":"3","key":"4502_CR12","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.tips.2014.01.004","volume":"35","author":"P Ruchala","year":"2014","unstructured":"P. Ruchala, E. Nemeth, The pathophysiology and Pharmacology of Hepcidin. Trends Pharmacol. Sci. 35(3), 155\u2013161 (2014)","journal-title":"Trends Pharmacol. Sci."},{"issue":"19","key":"4502_CR13","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.3390\/cancers13195001","volume":"13","author":"M Bianchi","year":"2021","unstructured":"M. Bianchi, G. Puliani, A. Chiefari, Metabolic and endocrine toxicities of mitotane: A systematic review. Cancers. 13(19), 5001 (2021)","journal-title":"Cancers"},{"issue":"1","key":"4502_CR14","doi-asserted-by":"publisher","first-page":"16222","DOI":"10.1038\/s41598-019-52715-3","volume":"9","author":"A. Hernik","year":"2019","unstructured":"A. Hernik, E. Szczepanek-Parulska et al., The Hepcidin concentration decreases in hypothyroid patients with hashimoto\u2019s thyroiditis following restoration of euthyroidism. Sci. Rep. 9(1), 16222 (2019)","journal-title":"Sci. Rep."},{"key":"4502_CR15","doi-asserted-by":"publisher","first-page":"1141603","DOI":"10.3389\/fonc.2023.1141603","volume":"13","author":"F. Lin","year":"2023","unstructured":"F. Lin, A. Tuffour, G. Hao, Distinctive modulation of Hepcidin in cancer and its therapeutic relevance. Front. Oncol. 13, 1141603 (2023)","journal-title":"Front. Oncol."},{"key":"4502_CR16","doi-asserted-by":"publisher","first-page":"788247","DOI":"10.3389\/fendo.2021.788247","volume":"2","author":"A. Krygier","year":"2022","unstructured":"A. Krygier et al., Iron homeostasis and Hepcidin concentration in patients with acromegaly. Front. Endocrinol. 2, 788247 (2022)","journal-title":"Front. Endocrinol."},{"issue":"3","key":"4502_CR17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1530\/EC-20-0017","volume":"9","author":"A. Krygier","year":"2020","unstructured":"A. Krygier, E. Szczepanek-Parulska, D. Filipowicz, M. Ruchala, Changes in serum Hepcidin according to thyrometabolic status in patients with graves\u2019 disease. Endocr. Connect. 9(3), 234\u2013242 (2020)","journal-title":"Endocr. Connect."},{"key":"4502_CR18","first-page":"5764061","volume":"019","author":"A Hernik","year":"2019","unstructured":"A. Hernik et al., Hepcidin and iron homeostasis in patients with subacute thyroiditis and healthy subjects. Mediators Inflamm. 019, 5764061 (2019)","journal-title":"Mediators Inflamm."},{"issue":"18","key":"4502_CR19","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.7150\/jca.31598","volume":"10","author":"P.-F. Wang","year":"2019","unstructured":"P.-F. Wang, S.-Y. Song, H. Guo, Prognostic role of pretreatment red blood cell distribution width in patients with cancer: A meta-analysis of 49 studies. J. Cancer. 10(18), 4305\u20134317 (2019)","journal-title":"J. Cancer"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04502-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04502-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04502-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T10:52:29Z","timestamp":1770029549000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04502-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4502"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04502-6","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving human participants were reviewed and approved by the Bioethical Committee of Poznan University of Medical Sciences. The patients provided their written informed consent to participate in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"52"}}